Cosmo Pharmaceuticals Confirms No Exposure to Proposed U.S. Tariffs and Reaffirms Growth Momentum

Rhea-AI Summary

Cosmo Pharmaceuticals (OTC:CMOPF) has addressed market concerns regarding potential U.S. tariffs on Swiss pharmaceutical companies, confirming that its operations and revenue streams remain unaffected. The company emphasized that it does not export products from Switzerland to the United States and operates through long-term contracts with global partners.

The company has reported increased EBITDA in its latest half-year results and maintains a positive outlook on its growth trajectory, supported by strong fundamentals and continued execution of its strategic plan.

Positive

• Company confirms no exposure to potential U.S. tariffs on Swiss pharmaceuticals
• Operations secured through long-term contracts with global partners
• Increased EBITDA reported in latest half-year results

Negative

• None.

Dublin, Ireland--(Newsfile Corp. - August 6, 2025) - Cosmo Pharmaceuticals N.V. (“Cosmo”) notes the recent market volatility following reports on potential U.S. tariffs on Swiss pharmaceutical companies.

Cosmo confirms that its operations and revenue streams are not impacted by any potential U.S. tariff measures, as the Company does not export products from Switzerland to the United States and operates on long-term contracts with global partners.

Cosmo remains confident in its growth trajectory, supported by the Company’s strong fundamentals and recently increased EBITDA, as reported in the latest half-year results. The Company continues to execute on its strategic plan, delivering stable and reliable performance for its shareholders.

About Cosmo
Cosmo is a life sciences company focused on MedTech AI, dermatology, gastrointestinal diseases, and contract development and manufacturing (CDMO). We design, develop, and manufacture advanced solutions that address critical medical needs and raise the standard of care. Our technologies are trusted by leading global pharmaceutical and MedTech companies and reach patients and healthcare providers around the world. Guided by our purpose - Building Health Confidence - our mission is to empower patients, healthcare professionals, and partners by innovating at the intersection of science and technology. Founded in 1997, Cosmo is headquartered in Dublin, Ireland, with offices in San Diego (USA), and in Lainate, Rome, and Catania (Italy).
For more information, visit www.cosmohealthconfidence.com.

Financial calendar

H.C. Wainwright 27th Annual Global Investment Conference, New York City, USA Jefferies Global Healthcare Conference, London, United Kingdom ODDO BHF Forum, Lyon, France

September 8-10, 2025 November 17-20, 2025 January 8-9, 2026

For further information, please contact:
investor.relations@cosmohc.com

Attachments

PDF - English

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/261483

FAQ

Will Cosmo Pharmaceuticals (CMOPF) be affected by the proposed U.S. tariffs on Swiss pharmaceutical companies?

No, Cosmo Pharmaceuticals confirmed it has no exposure to potential U.S. tariffs as it does not export products from Switzerland to the United States.

How does Cosmo Pharmaceuticals protect its revenue streams from trade uncertainties?

Cosmo operates through long-term contracts with global partners, which helps ensure stable and reliable performance.

What was reported in Cosmo Pharmaceuticals' latest half-year results?

The company reported an increase in EBITDA in its latest half-year results, demonstrating strong fundamentals.

What is the current growth outlook for Cosmo Pharmaceuticals (CMOPF)?

Cosmo remains confident in its growth trajectory, supported by strong fundamentals and successful execution of its strategic plan.